Home > Companies > Medseven Healthcare

Medseven Healthcare

“Our principle is to help our target market look and feel better in every aspect possible by building a healthy environment.” With presence over the course of four decades in United Arab Emirates, our board of directors at MEDSEVEN has excelled in Retail Pharmacy Industry. MEDSEVEN is a leading distribution company in UAE supplying Medical, Pharmaceutical and Generic and Cosmetic products over 135 target Retail Pharmacies in the industry. The company which is incorporated from seven pharmaceutical tycoons has its portfolio over 2500 products from Medical Supplies to imported generic items mostly from EU, North America, Australia and Asia. We’re in addition expanding and serving UAE market with our own product establishment known as Medseven One.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

PLANT BIOLOGY AND BIOTECHNOLOGY

Conference

Deuel Conference on Lipids

Conference

Plant Cell & Tissue Culture In Vitro IV

Conference

YEAST LIPID CONFERENCE 2022

Conference

The Mobile DNA Conference: Evolution, Diversity, and Impact

Conference

4th International Webinar on Nucleic Acids and CRISPR

Webinar

Related News

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCE PARTNERSHIP TO DEVELOP AND SCALE PRODUCTION OF COVID-19 SEROLOGY TEST

Bio-Techne | May 19, 2020

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System ("Mount Sinai") and Renalytix AI (LSE: RENX) formed exclusively to ensure that diagnostic tests for critical h...

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

MEDICAL

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele | July 27, 2020

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...